anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits (see WARNINGS: Pregnancy). CellCept tablets should not be crushed and CellCept capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in CellCept capsules and CellCept Oral Suspension (before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water. Should a spill occur, wipe up using paper towels wetted with water to remove spilled powder or suspension. Caution should be exercised in the handling and preparation of solutions of CellCept Intravenous. Avoid direct contact of the prepared solution of CellCept Intravenous with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.
The structure of cellular prion proteins encoded by the prion protein gene (PRNP) impacts susceptibility to transmissible spongiform encephalopathies, including chronic wasting disease (CWD) in deer. The recent emergence of CWD in Northern European reindeer (Rangifer tarandus), moose (Alces alces alces) and red deer (Cervus elaphus), in parallel with the outbreak in North America, gives reason to investigate PRNP variation in European deer, to implement risk assessments and adjust CWD management for deer populations under threat. We here report PRNP-sequence data from 911 samples of German red, roe (Capreolus capreolus), sika (Cervus nippon) and fallow deer (Dama dama) as well as additional data from 26 Danish red deer close to the German border and four zoo species not native to Germany. No PRNP sequence variation was observed in roe and fallow deer, as previously described for populations across Europe. In contrast, a broad PRNP variation was detected in red deer, with non-synonymous polymorphisms at codons 98, 226 and 247 as well as synonymous mutations at codons 21, 78, 136 and 185. Moreover, a novel 24 bp deletion within the octapeptide repeat was detected. In summary, 14 genotypes were seen in red deer with significant differences in their geographical distribution and frequencies, including geographical clustering of certain genotypes, suggesting "PRNP-linages" in this species. Based on data from North American CWD and the genotyping results of the European CWD cases, we would predict that large proportions of wild cervids in Europe might be susceptible to CWD once introduced to naive populations.
<P>PROBLEM TO BE SOLVED: To provide an antioxidant which inhibits the generation of active oxygen and radicals in vivo, inhibits the production of lipid peroxides, and can thereby prevent and treat aging of skins such as deterioration in the elasticity of the skins, the inflammation of the skins, and the pigmentation of the skins.  <P>SOLUTION: There is provided the antioxidant characterized by containing an extract of one or more plants selected from Iris ensata var. ensata, Iris sanguinea Hornem., and Iris laevigata Fisch. as an active ingredient. The antioxidant has an active oxygen-scavenging action and/or a radical-scavenging action, and can be used as a radical scavenger, an active oxygen-scavenger. Also, there is provided a cosmetic containing the antioxidant.  <P>COPYRIGHT: (C)2010,JPO&INPIT
After acute burn injury, patients experience a hypermetabolic state often complicated by a stress-induced hyperglycemia. Recent research points towards glycemic variability as a contributing factor in adverse outcomes in critically ill patients. In burn patients, greater glycemic variability has been associated with increased rates of mortality and sepsis. However, no studies to date have examined the impact of glycemic variability on rates of infection in this population or determined which measure may be most useful. Infection, and subsequent sepsis, remains the leading contributor to morbidity and mortality after burn injury. The primary objective of this study is to evaluate the relationship between different measures of glycemic variability and infectious complications in burn patients. This retrospective study included patients admitted to a single American Burn Association-verified burn center between January 1, 2020 and December 31, 2020 with burn or inhalation injury. The primary outcome was a composite of autograft loss, mortality, and proven infection. Secondary outcomes included hospital length of stay and a further analysis of the proven infection component of the composite primary outcome. In addition to mean glucose, several different measures of glycemic variability were used for comparison, including standard deviation, coefficient of variation, mean amplitude of glycemic excursions, and J-index. Outcomes were analyzed using multiple logistic regression analysis while controlling for revised Baux score. A quantile analysis was performed to do determine the optimal mean threshold. Three hundred and ninety-two patients were admitted and screened for inclusion during the study period. Most patients were excluded due to a LOS less than 72 h. 112 patients were included in the study. Of the 112 patients, 22.3% experienced an infectious complication (25 patients with 28 complications). Mean glucose (OR 1.024; 95% CI 1.004-1.045) and J-index (OR 1.044; 95% CI 1.003-1.087) were associated with occurrence of infectious complications. Regarding target mean glucose threshold, a daily mean glucose above 150 mg/dL showed the strongest association with infectious complications (OR 3.634; 95% CI 1.008-13.101). Mean glucose, standard of deviation, and J-index were all independently associated with proven infection.
PROBLEM TO BE SOLVED: To obtain skin-protecting cream excellent in water repellent property and durability in kitchen work. SOLUTION: This skin-protecting cream contains a volatile cyclic silicone oil (e.g. octamethylcyclotetrasiloxane or decamethylcyclopentasiloxane) which is a volatile oil or volatile isoparaffin (e.g. light liquid paraffin), a solid-like oil (e.g. natural wax), semi-solid-like oil (e.g. lanolin or vaseline) or a liquid oil (natural squalane) which are each a film-forming component, preferably further scaly powder (e.g. silicone hydrophobic tale powder or sericite) and an oil-soluble medicine (e.g. glycyrrhetic acid derivative or oil extract of Artemisiae capillaris flos) or a water-soluble medicine and does not contain water and a surface active agent (e.g. emulsifying agent).  Thereby, when the skin-protecting cream is applied to the surface of skin of hands, etc., a film excellent in water repellent property, durability, resilience and flexibility and free from stickiness is formed after volatile oil is volatilized.
Brucellosis, a chronic zoonotic disease with a significant global burden, particularly in endemic areas, can also present as neurobrucellosis, a rare complication. We report a case of polyradiculoneuropathy in a pediatric patient resulting from this uncommon presentation. A 5-year-old girl presented with progressive asymmetric lower limb weakness for two weeks that progressed to a loss of ambulation in four weeks. She also had flu-like symptoms and persistent high-grade fever. Her history was notable for ingesting raw milk before the onset of fever. Initial examination revealed meningismus signs and fever. She had bilateral weak hip flexion graded 4/5 on the Medical Research Council (MRC) scale, weak right and left knee flexion (3/5 and 4/5, respectively), and weak right ankle dorsiflexion (4/5). She also had diminished reflexes throughout. The patient exhibited a clinical picture resembling Guillain-Barré Syndrome (GBS) after admission as her weakness progressed. Cerebrospinal fluid (CSF) analysis revealed no cell counts, elevated protein levels (1545 mg/dL), and normal glucose levels (3.34 mmol/L). Blood and CSF cultures were negative, but the serum antibody titer was elevated at 1:1280 against Brucella melitensis and Brucella abortus species. Lumbosacral MRI showed diffuse enhancement of the lower nerve roots. A nerve conduction study (NCS) demonstrated axonal and demyelinating polyradiculoneuropathy. The patient regained her strength three months after presentation, following a course of antibiotics. When evaluating patients with atypical manifestations resembling GBS, brucellosis should be considered an important differential diagnosis in endemic areas.
Research Overview - The overarching aim of this study is to improve health outcomes for patients presenting to EDs by modifying and testing a disability diagnostic tool. The investigators expect a more accurate and precise tool will lead to better discharge plans and referrals for ED patients, reduce morbidity and mortality, and reduce unnecessary hospital visits and costs. The investigators will develop the core set of indicators with face (logical) validity from our research team of disability, emergency medicine, and geriatric medicine experts and practitioners. These experts will choose which pieces of information need to be included and group the selected pieces of information into content areas. Each content area will contain pieces of information that measure the same unidimensional concept. The investigators go through a series of Rasch analyses to establish which sets of information are in fact unidimensional and form usable scales. The investigators will test the validity of this preliminary version of the RDDT on existing hospital data by using it to predict health outcomes. Finally the investigators will consult the panel of experts to determine which information items, if any, are essential and missing from each content area. If there are such items they will be added to the RDDT. As described in the Preliminary Studies section, previous measures of disability were used for persons in long term care (LTC) and thus, need to be validated for use in the ED. The retrospective analysis will determine which indicators have superior measurement properties for use in the ED, plus, the retrospective analyses will link ED patient disability to health outcomes a necessary external validation step. A modified RDDT will be used in the prospective phase of the study. As lengthy diagnostic tools are neither feasible nor practical in the ED, Rasch scales are more useful in that subsets scale well and retain their measurement properties that remain accurate and precise. The investigators will conduct a randomized clinical trial (prospective phase) allocating patients into the study arm utilizing the RDDT (new tool) to compare with the control arm (standard care using MOD) to determine which measure is more accurate and precise as a measure of disability. There are both retrospective and prospective aspects to this multi-methodological interdisciplinary study.
The present invention relates to a chemical substance for protection of brain nerve cell and the method for producing thereof. In the method, Streptomyces sp. 60910 which produces a chemical substance for protection of brain nerve cell from an actinomycetes strain with a protective activity for brain nerve cell is identified and cultured. Then, an aromatic peptide compound with protective activity for brain nerve cell, Complestatin is extracted. The physichemical and biological activities for the compound are measured. The result was found that the chemical substance is acted as a material for protection of brain nerve cell.
PURPOSE:To obtain the subject base material excellent in properties such as wettability, solubilizability and dispersability in dosage formation by adding a specified amount of ethylene oxide to a glycerolysis product or an ester interchange product respectively obtained with glycerin of a specified glyceride. CONSTITUTION:A vehicle base material for drugs obtained by adding 80-700 pts.wt. ethylene oxide to 100 pts.wt. glycerolysis product or ester interchange product respectively obtained with glycerin of a glyceride (e.g. hydrogenated castor oil) containing at least hydroxy stearate as its constituting fatty acid component and having >=40 iodine value and >=100 hydroxyl number. The above- mentioned base material is remarkably stable to chemical change due to oxidation, etc., low in hemolytic properties and biomembrane-stimulating properties, excellent in safety, capable of exhibiting the efficacy of the medicinal components sufficiently when formulated to a medicinal preparation and capable of physicochemically stable storage for a long period.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to a pharmaceutical composition containing a compound of the general formula or its salt:   where R 1  means thienyl, pyridyl, aryl; R 2  means hydrogen atom, alkyl, phenyl; R 3  and R 4  mean independently hydrogen atom or alkyl, or R 3  and R 4  taken together with adjacent N-atom mean 6-membered heterocycle; A means C 2 -C 6 -alkylene; W means direct bond, O, S or (CH 2 ) n ; n = 1 or 2; X, Y and Z can be similar or distinct and each means CH (the latter can be a substituted alkyl), or N-atom. However, X, Y and Z can not mean CH simultaneously. Synthesized compounds exhibit the strong inhibiting activity with respect to neurons death and can be used as a therapeutic drug in cerebrovascular sicknesses. EFFECT: improved method of synthesis, enhanced effectiveness of drug. 17 cl, 1 tbl, 40 ex
Usual care for HF patients included the following: 1) Referral to HF clinic if the patient has no usual source of HF outpatient care, 2) HF patient education by HF care coordinator (advanced practice nurse), and 3) HF self care guide. All participants were treated by their usual source of HF care in the usual manner.
PURPOSE:To provide the subject composition improved in the abhesivity to the dentine along with its reinforcement, incorporated with a compound having a carbodiimide in the molecule. CONSTITUTION:The objective composition is incorporated with pref. 0.1-20 (esp. 0.5-10.0)wt.% of a compound having in the molecule a carbodiimide of the formula (A and A' are each alkyl, substituted alkyl, aromatic group, or may be combined with each other to form a ring structure) [esp. pref. cyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide or 1- cyclohexyl-3-(2-morphorinoethyl)carbodiimide]. This composition gives high adhesivity to esp. the dentine, and in the observation of its adaptability to removed human teeth, the resin-dentine bonding state is favorable, and there are entirely no gaps considered as the most probable factor for secondary dental caries.
In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
The present invention discloses meat odor type superfine powder of livestock and poultry bones, and the preparation technology thereof. The superfine powder is prepared from superfine powder of livestock and poultry bone and edible additive, attritioning, enzymolysis and oil removal are carried out to the superfine powder used as raw materials, and the edible additive is used as an auxiliary material. The superfine powder contains raw materials by the weight percentage: 0.02% to 20% of food filler, 0.0001% to 0.05% of antioxidant and surplus superfine powder of livestock and poultry bones. The preparation technology comprises: attritioning is carried out to fresh bones, enzymolysis is carried out at the temperature of 50 DEG C to 65 DEG C with the pH value of 6.5 to 7.0, then centrifugation and oil removal are carried out, and the fatty amount of materials is at most 10%; adding auxiliary materials are orderly added, temperature is kept for 0.5 to 1 hour at the temperature of 80 DEG C to 95 DEG C, and then spray drying is carried out at temperature of 75 DEG C to 95 DEG C. In the present invention, temperature for processing fresh bones is low, and nutrient components in the bones are completely preserved. Protein in the bones is changed into amino acid and peptide with small molecules by enzymolysis biotechnology, and thus, the product is rich in nutrient components, such as calcium, phosphorus, amino acid, peptide with small molecules, etc. After being processed by special biotechnology, various nutrient components of bones are favorable to preservation, and are easy to absorb by human bodies.
The use of a composition comprising an oil phase, an aqueous phase, at least one water-in-oil emulsifying agent and at least one oil-in-water emulsifying agent, in the from of inverse latex comprising an anionic polyelectrolyte (20-70, preferably 25-40, wt. %) for the preparation of cosmetic, dermopharmaceutical or pharmaceutical compositions is new. The use of a composition comprising an oil phase, an aqueous phase, at least one water-in-oil emulsifying agent and at least one oil-in-water emulsifying agent, in the from of inverse latex comprising an anionic polyelectrolyte (20-70, preferably 25-40, wt. %) for the preparation of cosmetic, dermopharmaceutical or pharmaceutical compositions is new. The anionic polyelectrolyte comprises acrylic acid units partially neutralized and optionally branched and/or reticulated. Independent claims are also included for: (1) a composition comprising an oil phase, an aqueous phase, at least one water-in-oil emulsifying agent and at least one oil-in-water emulsifying agent, in the from of inverse latex comprising a reticulated anionic polyelectrolyte (20-70, preferably 25-40, wt. %), the reticulating agent being a compound containing at least two allyl radicals such as diallyloxy acetic acid, sodium diallyloxy acetate or tri allylamine; (2) the preparation of the composition comprising: (a) emulsifying an aqueous solution containing monomers and optionally additives in an oil phase in the presence of at least one water-in-oil emulsifying agent; (b) initiating a polymerization reaction in the emulsion by adding a free radical initiator and optionally a co-initiator; and (c) adding at least one oil-in-water emulsifying agent at less than 50 degrees C, after the polymerization reaction finished, and optionally after concentration of the mixture; and (3) the preparation of a cosmetic, dermopharmaceutical or pharmaceutical comprising the above described composition (0.1-10 wt. %).
Background & objectives Acute tonsillitis is a disease that can often be cured with medical treatment. However, complications may occur during this disease process. One of these complications is peritonsillar abscess. In recent years, biomarkers have been frequently used in the diagnosis of diseases. The aim of the study was to reveal whether peritonsillar abscess develops after acute tonsillitis, and acute tonsillitis can be differentiated using biomarkers and which biomarker has higher predictive value for this differentiation. Methods The control group consisted of individuals who were operated for septoplasty in the otolaryngology clinic, and the acute tonsillitis group consisted of individuals diagnosed with acute tonsillitis in the same clinic. Both groups were statistically compared in terms of mean platelet volume (MPV), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune inflammation index (SII), infection discrimination index (IDI), plateletcrit (PCT) and lymphocyte to monocyte ratio (LMR) biomarkers. Statistically, significant biomarker values were compared between the subgroups in the tonsillitis group of those who had only acute tonsillitis and those who had peritonsillar abscess due to acute tonsillitis. Receiver operating characteristics (ROC) curve analysis was performed on biomarkers for their ability to predict the presence of peritonsillar abscess. Results When the individuals who had only acute tonsillitis and those who had acute tonsillitis with peritonsillar abscess were compared in terms of biomarkers, there was a statistically significant difference between the mean MPV, SII and PCT (P=0.010, 0.021, 0.023, respectively). ROC analysis was performed to calculate the sensitivity and specificity of MPV, PCT and SII for the diagnosis of acute tonsillitis with peritonsillar abscess (sensitivity-specificity for MPV 51.9-72.7%, for SII 94.2-32.7%, for PCT 71.2-50.9%, respectively). Interpretation & conclusions MPV, SII and PCT biomarkers may be useful to help clinicians predict peritonsillar abscess due to acute tonsillitis.
A dental filling material comprising a thermoplastic polymer. The thermoplastic polymer may be biodegradable. A bioactive substance may also be included in the filling material. The thermoplastic polymer acts as a matrix for the bioactive substance. The composition may include other polymeric resins, fillers, plasticizers and other additives typically used in dental materials. The filling material is used for the filing of root canals.
ACTIVE Vitamin D = Vitamin D3, one 2000 IU capsule/day; ACTIVE Omega-3 Fatty Acids = Omacor, one 1-gram capsule/day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Acute pancreatitis is a common systemic inflammatory disease, manifested by a spectrum of severity, ranging from mild in the majority of patients to severe acute pancreatitis. Patients with severe acute pancreatitis suffer from severe local and systemic complications and organ failure, leading to a poor prognosis. The early recognition of the severe condition is important to improve prognosis. Obesity has risen in tandem with an increase in the severity of acute pancreatitis in recent years. Studies have revealed that adipose tissue, particularly visceral adipose tissue is associated with the prognosis of acute pancreatitis. This review discussed the role of visceral adipose tissue in obese patients with acute pancreatitis and explored the possible mechanism involved.
Blackgram (Vigna mungo L. Hepper) production is hindered by mungbean yellow mosaic virus (MYMV) with disease incidence up to 85% in hot spot locations of Tamil Nadu, India. Field screening of 50 genotypes identified Mash 114 as resistant and CO 5 as susceptible cultivars. To understand the resistance mechanism, temporal metabolome variations of resistant (RC) and susceptible (SC) cultivars were assessed at 3, 6, and 12 days post-inoculation with MYMV via whitefly transmission using GC-MS. The study included aviruliferous whitefly and healthy controls. Data analysis identified 98 differential compounds across various metabolic groups. Principal component analysis (PCA) and hierarchical cluster analysis (HCA) revealed distinct metabolic profiles, with RC accumulating antiviral terpenoids such as ursolic acid, betulin, and umbelliprenin, while SC upregulated lipids and fatty acids favoring virus replication. These findings provide insights for breeders to identify resistant sources and pave the way for improved MYMV management strategies using antiviral products.
Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.